View Financial HealthBeyondSpring 배당 및 자사주 매입배당 기준 점검 0/6BeyondSpring 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-3.2%자사주 매입 수익률총 주주 수익률-3.2%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesCan BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth?Apr 28BeyondSpring Inc Reports Compelling New Data on Plinabulin Advances Both the Anticancer Efficacy and Safety of Adc DrugsApr 24New major risk - Financial position Mar 26BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3Dec 12Beyondspring Inc. Announces New Post-Hoc Analyses from Its Global Phase 3 Dublin-3StudyDec 11BeyondSpring Inc. has completed a Follow-on Equity Offering in the amount of $2 million.Nov 22BeyondSpring Inc. has filed a Follow-on Equity Offering in the amount of $2 million.Nov 18We Think BeyondSpring (NASDAQ:BYSI) Needs To Drive Business Growth CarefullySep 24Insufficient new directors Sep 01BeyondSpring Inc. Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor FailureJul 07BeyondSpring Inc., Annual General Meeting, Sep 15, 2025Jul 06New major risk - Share price stability Jun 12Here's Why BeyondSpring (NASDAQ:BYSI) Must Use Its Cash WiselyJun 10BeyondSpring Inc. Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual MeetingJun 03New minor risk - Share price stability May 06New major risk - Revenue size Mar 28New minor risk - Financial data availability Mar 17BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual MeetingNov 12BeyondSpring Inc. Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-Type NSCLC at NSCLC Congress 2024Sep 16First half 2024 earnings released: US$0.19 loss per share (vs US$0.33 loss in 1H 2023) Sep 02New minor risk - Shareholder dilution Sep 01New minor risk - Market cap size Apr 09BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price RuleFeb 28First half 2023 earnings released: US$0.33 loss per share (vs US$0.47 loss in 1H 2022) Feb 07New major risk - Revenue and earnings growth Dec 31BeyondSpring Inc. Announces New Data That Translates Preclinical Proof-Of-Concept to Clinical Evidence of Plinabulin’s Immunomodulating ActivityNov 08New minor risk - Financial data availability Nov 05BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price RequirementOct 31New major risk - Share price stability Oct 13BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price RequirementsOct 05BeyondSpring Inc. Announces Retirement of Yanbin Xie as Board of DirectorJul 15Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn SituationJun 21BeyondSpring Inc. Announces New Data from Phase 1 Investigator Initiated Study Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCTJun 08Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 19BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing RulesJan 10BeyondSpring Inc. Announces the Resignation of Christine Ying Zhao from the Board of Directors, Effective January 1, 2023Jan 01BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price RequirementsNov 24Price target decreased to US$2.30 Nov 16BeyondSpring Inc. Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022Sep 14BeyondSpring Inc. Announces Board AppointmentsAug 30+ 1 more updateBeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell 2000 Dynamic IndexJun 26BeyondSpring Inc. Announces Executive Resignations, with Effect from June 9, 2022Jun 14BeyondSpring Inc. Announces Resignation of Gordon L. Schooley as Chief Regulatory OfficerJun 10Price target decreased to US$6.10 May 02Elizabeth Czerepak Resigns as Executive Vice President of BeyondSpring IncApr 23+ 1 more updateConsensus forecasts updated Apr 21Price target increased to US$13.67 Apr 14BeyondSpring Inc. to Report Q4, 2021 Results on Apr 14, 2022Apr 09BeyondSpring, Beyond Salvage Feb 03BeyondSpring Pharmaceuticals Announces Organizational StreamliningJan 12Consensus revenue estimates fall by 90% Jan 07BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin’s Fast Onset Mechanism of Action in Prevention of Chemotherapy-Induced Neutropenia at 63rd ASH Annual Meeting and ExpositionDec 16Consensus forecasts updated Dec 03BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia (CIN)Dec 02No longer forecast to breakeven Nov 25Circling Back On BeyondSpring Nov 16Price target decreased to US$58.60 Sep 21Upcoming News For BeyondSpring's Plinabulin Tees Up Big Potential Returns Sep 18BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk Sep 07Price target increased to US$67.25 Aug 05BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space Aug 01Consensus forecasts updated Jun 30BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell Microcap Value IndexJun 28+ 4 more updatesConsensus forecasts updated Jun 23BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual MeetingJun 11BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim and Offers Superior Prevention of Chemotherapy-Induced Neutropenia (CIN) at the FOCIS Annual MeetingJun 09BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid TumorsJun 05BeyondSpring Inc. Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced NeutropeniaJun 02BeyondSpring Announces Five Presentations at the American Society of Clinical Oncology (ASCO) Annual MeetingApr 29Chief Scientific Officer has left the company Mar 21BeyondSpring Inc. Announces Management ChangesMar 21Price target lowered to US$36.00 Dec 30How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?Dec 22BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of DirectorsDec 19BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer SymposiumDec 11BeyondSpring Inc. has completed a Follow-on Equity Offering in the amount of $75 million.Nov 20BeyondSpring Announces Positive Topline Results from Its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Prevention of Chemotherapy-Induced NeutropeniaNov 17New 90-day high: US$16.02 Nov 07BeyondSpring Forms Partnership Advisory CommitteeOct 13New 90-day high: US$15.36 Oct 10BeyondSpring Inc. Announces JAMA Oncology Highlights Plinabulin's Efficacy in Preventing Chemotherapy-Induced Neutropenia as a MonotherapyOct 04BeyondSpring Inc. Announces New Clinical Data on Late-Stage Asset, PlinabulinSep 26BeyondSpring Inc. Appoints Elizabeth Czerepak as Chief Financial OfficerSep 24BeyondSpring Inc. to Report Q2, 2020 Results on Sep 03, 2020Aug 29BeyondSpring Inc. announced that it expects to receive $4.999995 million in funding from Decheng Capital LLCJun 20+ 1 more update지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 BYSI 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: BYSI 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장BeyondSpring 배당 수익률 vs 시장BYSI의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (BYSI)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.5%분석가 예측 (BYSI) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 BYSI 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 BYSI 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 BYSI 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: BYSI 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/05 07:30종가2026/05/05 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BeyondSpring Inc.는 9명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Joel BeattyBairdJason Matthew GerberryBofA Global ResearchJoshua SchimmerEvercore ISI6명의 분석가 더 보기
BeyondSpring Inc Reports Compelling New Data on Plinabulin Advances Both the Anticancer Efficacy and Safety of Adc DrugsApr 24
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3Dec 12
BeyondSpring Inc. Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor FailureJul 07
BeyondSpring Inc. Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual MeetingJun 03
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual MeetingNov 12
BeyondSpring Inc. Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-Type NSCLC at NSCLC Congress 2024Sep 16
BeyondSpring Inc. Announces New Data That Translates Preclinical Proof-Of-Concept to Clinical Evidence of Plinabulin’s Immunomodulating ActivityNov 08
BeyondSpring Inc. Announces New Data from Phase 1 Investigator Initiated Study Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCTJun 08
BeyondSpring Inc. Announces the Resignation of Christine Ying Zhao from the Board of Directors, Effective January 1, 2023Jan 01
BeyondSpring Inc. Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022Sep 14
BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin’s Fast Onset Mechanism of Action in Prevention of Chemotherapy-Induced Neutropenia at 63rd ASH Annual Meeting and ExpositionDec 16
BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia (CIN)Dec 02
BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual MeetingJun 11
BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim and Offers Superior Prevention of Chemotherapy-Induced Neutropenia (CIN) at the FOCIS Annual MeetingJun 09
BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid TumorsJun 05
BeyondSpring Inc. Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced NeutropeniaJun 02
BeyondSpring Announces Five Presentations at the American Society of Clinical Oncology (ASCO) Annual MeetingApr 29
BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer SymposiumDec 11
BeyondSpring Announces Positive Topline Results from Its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Prevention of Chemotherapy-Induced NeutropeniaNov 17
BeyondSpring Inc. Announces JAMA Oncology Highlights Plinabulin's Efficacy in Preventing Chemotherapy-Induced Neutropenia as a MonotherapyOct 04
BeyondSpring Inc. announced that it expects to receive $4.999995 million in funding from Decheng Capital LLCJun 20+ 1 more update
